We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
(Approval lapsed) Neostigmine Methylsulfate Injection 2.5mg in 1mL Ampoule (Hameln Pharma, UK)
Section 19A approved medicine
(Approval lapsed) Neostigmine Methylsulfate Injection 2.5mg in 1mL Ampoule (Hameln Pharma, UK)
Section 19A approval holder
Juno Pharmaceuticals Pty Ltd ABN 55 156 303 650
Phone
03 8888 1288
Approved until
Status
Expired
Medicines in short supply/unavailable
NEOSTIGMINE JUNO neostigmine methylsulfate 2.5 mg/1 mL solution for injection ampoule - ARTG 219054
Indication(s)
Neostigmine is indicated for:
- Reversal of the effects of non-depolarising neuromuscular blocking agents.
- Prophylaxis and treatment of post-operative intestinal atony and urinary retention.
- Treatment of myasthenia gravis during acute exacerbations, when the condition is severe or in neonates.
Images
